GBG Research at ESMO Breast Cancer Virtual Meeting 2021


GBG Research at ESMO Breast Cancer Virtual Meeting 2021

We are delighted to inform you that results of several research projects from GBG and collaborative groups will be presented at the upcoming ESMO Breast Cancer Virtual Meeting 2021, which will take place from 5 to 8 May 2021.

Oral Presentations

#O2 Date: 07.05.2021, Lecture Time: 15:03 - 15:13, Session: Proffered Paper session 1
Speakers: A. Llop-Guevara (Barcelona, Spain)
Association of RAD51 with Homologous Recombination Deficiency (HRD) and clinical outcomes in untreated triple-negative breast cancer (TNBC): analysis of the GeparSixto randomized clinical trial
Llop-Guevara A, Vladimirova V, Schneeweiss A, et al.

Mini oral presentation #95MO Date: 08.05.2021 Lecture Time: 12:45 - 14:00, Session: Mini Oral session 2
Speakers: E. Laakmann (Hamburg, Germany)
Characteristics of patients with brain metastases from HER2-positive breast cancer
Laakmann E, Witzel I, Neunhöffer T, et al.


Date: 05.05.2021Session: ePoster Display Session

#17P Impact of body mass index (BMI) on prognostic and predictive value of stromal tumor-infiltrating lymphocytes (sTILs) in triple-negative breast cancer (TNBC): a pooled analysis of six neoadjuvant trials.
Furlanetto J, Denkert C, Untch M, et al.

#21P BACH1 and HIF1α predict response to neoadjuvant nab-paclitaxel (nP) treatment in early breast cancer (BC)
Vladimirova V, Schneeweiss A, Jackisch C, et al.

#28P EVI1 expression in early-stage breast cancer patients treated with neoadjuvant chemotherapy
Leichsenring J, Vladimirova V, Solbach C, et al.

#66P Baseline menopausal status, Ki-67 and stromal tumor-infiltrating lymphocytes (TILs) and association with outcome in triple-negative breast cancer (TNBC): exploratory analysis in GeparSixto
Labidi-Galy I, Schneeweiss A, Sinn HP, et al.


  • 18.11.2022 Desiree: dose escalation of everolimus published

    Desiree: dose escalation of everolimus published

    We are proud to inform you that our article A multicentre, randomised, double-blind, phase II study to evaluate the tolerability of an induction dose escalation of everolimus in patients with metastatic breast cancer (DESIREE; GBG 86) is now available online.

    Mehr ...
  • 10.11.2022 Deutscher Krebskongress

    Deutscher Krebskongress

    Die GBG ist mit mehreren Postern auf dem 35. Deutschen Krebskongress vom 13. – 16. November 2022 in Berlin vertreten.

    Mehr ...
  • 08.11.2022 GBG research at SABCS 2022

    GBG research at SABCS 2022

    We are proud to present our research at the San Antonio Breast Cancer Symposium, December 6-10

    Mehr ...
  • 14.10.2022 Location of Subcutaneous Trastuzumab Injection

    Location of Subcutaneous Trastuzumab Injection

    Subcutaneous injection of trastuzumab into the thigh versus abdominal wall in patients with HER2-positive early breast cancer: pharmacokinetic, safety and patients´ preference - substudy of the randomised phase III GAIN-2 study

    Mehr ...

GBG Forschungs GmbH
Dornhofstr. 10 | 63263 Neu-Isenburg | Fax +49 6102 7480-440

+49 6102 7480-0 | nfGBGd